Milestone Pharmaceuticals had $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024.
Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...
MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete ...
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 ...
MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response ...
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 ...
Fourth Quarter 2024 and Recent Program Updates CARDAMYST for patients with PSVT Etripamil for patients with AFib-RVR Milestone is on track to initiate a Phase 3 trial evaluating etripamil in AFib-RVR ...
Milestone (WA: MMD )’s President and CEO, Joe Oliveto, expressed the company’s disappointment with the CRL but reaffirmed their commitment to CARDAMYST as a potential novel treatment for PSVT. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback